- New York AG Letitia James entered an agreement with Novo Nordisk Inc. to resolve an investigation into insulin marketing and pricing practices.
- Under the terms of the agreement, Novo Nordisk will cap the price of their insulin products at $35 per monthly prescription for uninsured New Yorkers for a period of five years. The company also agreed to implement a streamlined process for notifying uninsured patients of their eligibility for the $35 monthly cap before they pay at the pharmacy counter and to continue providing free insulin to the highest-need consumers.
- As previously reported, AG James reached similar price cap agreements with insulin manufacturers Eli Lilly and Company and Sanofi-Aventis U.S. LLC.